Tracy Ryan
Founder NKore Bio Therapeutics
Tracy is an award-winning entrepreneur with 29 years of experience in building globally recognized brands, raising capital, philanthropy, pioneering research, and public speaking. Her journey has taken her across the world, sharing her family’s inspiring story of her daughter Sophie’s 7-year battle with a low-grade brain tumor, which has been featured by top media outlets. Tracy has founded and led several successful ventures, including an award-winning marketing and graphic design agency in Los Angeles, a globally recognized medical cannabis tincture company, and the 501(c)(3) nonprofit Saving Sophie, named after her daughter. She is currently the Co-Founder and Chief Communications Officer of NKore BioTherapeutics that currently holds the patents to a non-toxic natural killer cell immunotherapy that is reversing her daughter’s incurable brain tumor with no negative side effects.
Seminars
- Advancing first-in-human safety, early compassionate-use cases show no adverse events in patients treated with NK101, supporting a favorable emerging safety profile ahead of IND submission
- Demonstrating NK-cell persistence and immune engagement, immune-monitoring data show NK-cell levels rising from <2% to ~18% post-infusion in one patient, indicating meaningful in vivo activity
- Informing clinical development and indication strategy, early real-world experience is guiding prioritization, dosing, and translational endpoints as NKore moves toward first-in-human trials
A dynamic opening discussion featuring CEOs and founders at the forefront of innate immunity and NK-cell innovation. This high-level session sets the tone for the meeting as industry leaders examine the current landscape, emerging scientific and commercial inflection points, and the path to translating innate immune breakthroughs into meaningful therapeutic impact. Through candid insights and forward-looking perspectives, the panel will outline the opportunities, challenges, and decisive moves that will shape the field over the next 3–5 years.
- The milestones that brought innate therapies to today’s inflection point
- What’s driving the next wave of NK and innate innovation
- Scientific and clinical hurdles that must be overcome
- Strategic priorities in a shifting funding and regulatory climate
- Commercial pathways and competitive positioning for the next era
